AVIR vs. ORGO, SBTX, NLTX, FBLG, ERAS, RANI, KMDA, URGN, TERN, and VRCA
Should you be buying Atea Pharmaceuticals stock or one of its competitors? The main competitors of Atea Pharmaceuticals include Organogenesis (ORGO), Silverback Therapeutics (SBTX), Neoleukin Therapeutics (NLTX), FibroBiologics (FBLG), Erasca (ERAS), Rani Therapeutics (RANI), Kamada (KMDA), UroGen Pharma (URGN), Terns Pharmaceuticals (TERN), and Verrica Pharmaceuticals (VRCA). These companies are all part of the "pharmaceutical preparations" industry.
Organogenesis (NASDAQ:ORGO) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, valuation, dividends and community ranking.
Organogenesis received 79 more outperform votes than Atea Pharmaceuticals when rated by MarketBeat users. Likewise, 66.21% of users gave Organogenesis an outperform vote while only 47.22% of users gave Atea Pharmaceuticals an outperform vote.
Organogenesis has a net margin of 1.14% compared to Organogenesis' net margin of 0.00%. Atea Pharmaceuticals' return on equity of 1.81% beat Organogenesis' return on equity.
Organogenesis has a beta of 1.6, meaning that its stock price is 60% more volatile than the S&P 500. Comparatively, Atea Pharmaceuticals has a beta of 0.19, meaning that its stock price is 81% less volatile than the S&P 500.
49.6% of Organogenesis shares are owned by institutional investors. Comparatively, 86.7% of Atea Pharmaceuticals shares are owned by institutional investors. 34.0% of Organogenesis shares are owned by company insiders. Comparatively, 14.5% of Atea Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
In the previous week, Organogenesis and Organogenesis both had 2 articles in the media. Organogenesis' average media sentiment score of 0.38 beat Atea Pharmaceuticals' score of 0.27 indicating that Atea Pharmaceuticals is being referred to more favorably in the news media.
Organogenesis has higher revenue and earnings than Atea Pharmaceuticals. Atea Pharmaceuticals is trading at a lower price-to-earnings ratio than Organogenesis, indicating that it is currently the more affordable of the two stocks.
Organogenesis presently has a consensus target price of $4.83, indicating a potential upside of 106.55%. Given Atea Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Organogenesis is more favorable than Atea Pharmaceuticals.
Summary
Organogenesis beats Atea Pharmaceuticals on 14 of the 17 factors compared between the two stocks.
Get Atea Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVIR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AVIR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Atea Pharmaceuticals Competitors List
Related Companies and Tools
